National Healthcare Security Administration: Further improve the system of pharmaceutical pricing and procurement credit evaluation.

Recently, the National Health Security Administration issued a notice on further improving the medical price and procurement credit evaluation system, revising the system for price procurement credit evaluation, and recently, relevant officials of the National Health Insurance Administration accepted an interview with reporters. It was mentioned that the revision of this system is to better eliminate commercial bribery, sales with kickbacks, and other unfair trading behaviors, urge pharmaceutical companies to participate in market operations with integrity, optimize resource allocation, and play a very important role in purifying the industry ecology. On the other hand, it is also to more strictly regulate dishonest businesses, enforce strict measures, increase the cost of non-compliance for pharmaceutical companies, guide pharmaceutical companies to improve quality, enhance efficacy, sell products in compliance with regulations, enter the market through centralized procurement, national negotiations, etc., reduce dependence on the path of "high price, high rebate, low quality", and earn money in a fair and transparent manner.